Literatur
- 1
van Oosterom A T, Judson I, Verweij J. et al .
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours:
a phase I study.
Lancet.
2001;
358
1903
- 2
Demetri G D, von Mehren M, Blanke C D. et al .
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
N Engl J Med.
2002;
347
462-463
- 3
Heinrich M C, Corless C L, Duensing A. et al .
PDGFRA activating mutations in gastrointestinal stromal tumors.
Science.
2003;
299
708-710
- 4
Gunawan B, Bergamnn F, Höer J. et al .
Biological and clinical significance of cytogenetic abnormalities in low-risk and
high risk gastrointestinal stromal tumors.
Hum Pathol.
2002;
33
316-321
- 5
El-Rifai W, Sarlomo-Rikala M, Andersson L C. et al .
DNA sequence copy number changes in gastrointestinal stromal tumors: Tumor progression
and prognostic significance.
Cancer Res.
2000;
60
3899-3903
- 6
Schneider-Stock R, Boltze C, Lasota J. et al .
High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors.
J Clin Oncol.
2003;
21
1688-1697
Bastian Gunawan
Zentrum Pathologie, Georg-August-Universität
Robert-Koch-Str. 40
37099 Göttingen
eMail: bastian.gunawan@med.uni-goettingen.de
